Executive Summary: EHC Round Table on “Current Issues in von Willebrand Disease”
Other resources
Reflecting on 2025: a year of consolidation
Throughout 2025, we have strengthened our foundations as a credible and mature organisation, reinforced our collective voice, and further clarified our role in supporting National Member Organisations (NMOs) across Europe.
Update on Novo Nordisk manufacturing deviation for NovoSeven©, resulting in shortages for NovoEight© and Esperoct©
Mid-June 2024, the EHC, NBDF and WFH were made aware of a manufacturing deviation in the production lines of several products for the treatment of haemophilia and other coagulopathies manufactured by Novo Nordisk in Denmark.